Clinical trials: sponsored by UNICANCER
Metastatic Breast Cancer With a Isolated Brain Progression
Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer
The overall survival of patients with metastatic breast cancer has steadily improved over the past decades, mainly due to advances in systemic treatment.
- Trial name
- InTTercePT (NCT05041842)
- Testing
- Tucatinib, Pertuzumab, Trastuzumab
- Where
- 16 sites in France
- Volunteers
- 53 people
- Sponsor
- UNICANCER
Hepatocellular Carcinoma by BCLC Stage
Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions
Liver cancer is the third leading cause of cancer-related deaths worldwide. The majority of primary liver cancers occur as hepatocellular carcinoma (HCC), the incidence of which is increasing in many parts of the world.
- Trial name
- HESTIA (NCT05622071)
- Testing
- Tislelizumab
- Where
- 10 sites in France
- Volunteers
- 50 people
- Sponsor
- UNICANCER
Triple Negative Breast Neoplasms
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
The goal of this clinical trial is to evaluate the efficacity and safety of pembrolizumab and capecitabine on the invasive disease-free survival, in participants who have triple negative breast cancer (TNBC) with residual disease…
- Trial name
- CAPPA (NCT05973864)
- Testing
- Pembrolizumab injection, Capecitabine tablets, Local radiotherapy
- Where
- 20 sites in France
- Volunteers
- 220 people
- Sponsor
- UNICANCER
Oropharynx Squamous Cell Carcinoma
SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal Cancers
SURVEILLE-HPV - A new post therapeutic surveillance strategy for HPV-driven oropharyngeal cancer based on HPV Circulating DNA measures.
- Trial name
- SURVEILLE-HPV (NCT05582122)
- Testing
- HPV16 Ct-DNA dosing
- Where
- 16 sites in France
- Volunteers
- 420 people
- Sponsor
- UNICANCER
Solid Tumors, Hematologic Cancers
Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations
Patients with metastatic or unresectable locally advanced malignancies harboring BRAF genomic alterations, the biological target of vemurafenib, and who are no more amenable to curative treatment.
- Conditions
- Solid Tumors, Hematologic Cancers, Metastatic Cancers
- Trial name
- AcSé (NCT02304809)
- Testing
- Vemurafenib
- Where
- France
- Volunteers
- 216 people
- Sponsor
- UNICANCER
Adenocarcinoma of Prostate, Progression of Prostate Cancer
A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse
The objective of this study is to assess the effect of neoadjuvant cabazitaxel and pelvic radiotherapy in combination with androgen deprivation therapy (ADT)-radiotherapy on clinical progression-free survival in patients with…
- Trial name
- PEACE2 (NCT01952223)
- Testing
- Cabazitaxel, Pelvic radiotherapy, prostate radiotherapy
- Where
- France
- Volunteers
- 761 people
- Sponsor
- UNICANCER
Prostate Cancer
Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy
This is a multicenter, randomized, open label, phase III study comparing the efficacy and safety of apatulamide combined with concomitant prostate-bed salvage radiotherapy (SRT) and androgen deprivation therapy (ADT) versus…
- Trial name
- CARLHA-2 (NCT04181203)
- Testing
- Apalutamide, Salvage radiotherapy (SRT), Luteinising Hormone Releasing Hormone agonist (LHRHa)
- Where
- 15 sites in France
- Volunteers
- 490 people
- Sponsor
- UNICANCER
Penile Cancer, Squamous Carcinoma
Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis
Squamous cell carcinoma of the penis is a rare tumor in Europe, whose prognosis and survival are influenced by metastatic lymph node involvement. Its frequency in France is estimated at less than 1% of human cancers.
- Trial name
- MEGACEP (NCT02817958)
- Testing
- Chemotherapy TIP
- Where
- 17 sites in France
- Volunteers
- 37 people
- Sponsor
- UNICANCER
Oligometastatic Hormone Sensitive Prostate Cancer
Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients
INDICATION: Oligometastatic hormone-sensitive prostate cancer patients. METHODOLOGY: Open label, double arm, randomized 1:1, multicenter phase III study.
- Trial name
- Oligo-PRESTO (NCT04115007)
- Testing
- Stereotactic Body Radiotherapy (SBRT) + Standard of care, Standard of care
- Where
- 35 sites in France, Martinique
- Volunteers
- 550 people
- Sponsor
- UNICANCER
Cancer of the Rectum
Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer
National, multi-center, open-label,randomized, 2-arm phase III superiority trial, comparing neoadjuvant chemotherapy (CT) with mFolfirinox followed by preoperative chemoradiotherapy (CRT), versus preoperative CRT in patients with…
- Trial name
- Néofirinox (NCT01804790)
- Testing
- mFolfirinox, Radiotherapy 50 Gy, Capecitabine
- Where
- 36 sites in France
- Volunteers
- 461 people
- Sponsor
- UNICANCER
Breast Tumors
Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis
Multicenter, open-label phase II trial assessing the efficacy of DS-8201a monotherapy in patients with metastatic breast cancer.
- Trial name
- DAISY (NCT04132960)
- Testing
- DS-8201a
- Where
- 15 sites in France
- Volunteers
- 186 people
- Sponsor
- UNICANCER
Sarcoma
Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- OS2006 (NCT00470223)
- Testing
- cisplatin, doxorubicin hydrochloride, etoposide
- Where
- 37 sites in France
- Volunteers
- 318 people
- Sponsor
- UNICANCER
Prostate Cancer
Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as triptorelin, may lessen the amount of androgens made by the body. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00667069
- Testing
- triptorelin, adjuvant therapy, 3-dimensional conformal radiation therapy
- Where
- 17 sites in France
- Volunteers
- 424 people
- Sponsor
- UNICANCER
Solid Tumor, Miscellaneous
Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells
Alterations in the fibroblast growth factor receptor (FGFR) gene are involved in the development of cancer. These anomalies are found at very variable frequencies (from less than 1% to around 10%) in cancers of the bile ducts…
- Trial name
- AcSé PEMI (NCT06653777)
- Testing
- Pemigatinib
- Where
- 6 sites in France
- Volunteers
- 40 people
- Sponsor
- UNICANCER
Breast Cancer, Lumpectomy
Standard or Hypofractionated Radiotherapy Versus Accelerated Partial Breast Irradiation (APBI) for Breast Cancer
The standard treatment for localized breast cancer is based on conservative surgery (when possible) followed by radiation therapy (RT) delivered to the whole breast.
- Trial name
- SHARE (NCT01247233)
- Testing
- Whole Breast Irradiation + Boost or Hypofractionated irradiation, Accelerated partial breast irradiation
- Where
- 34 sites in France
- Volunteers
- 1,006 people
- Sponsor
- UNICANCER
Metastatic Colorectal Cancer
Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer
A randomized, phase II study comparing the sequences of regorafenib and trifluridine/tipiracil, after failure of standard therapies in patients with metastatic colorectal cancer
- Trial name
- SOREGATT (NCT04450836)
- Testing
- Regorafenib then Trifluridine/Tipiracil, Trifluridine/Tipiracil then Regorafenib
- Where
- 36 sites in Belgium, France
- Volunteers
- 234 people
- Sponsor
- UNICANCER
Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma
Comparison of Oral Cyclophosphamide vs Doxorubicin in ≥65 Years Old Advanced or Metastatic Soft Tissue Sarcoma Patients
Most advanced or metastatic soft tissue sarcoma (STS) are unfortunately incurable, making the preservation of the patient's quality of life a major goal, along with prolonging survival.
- Trial name
- GERICO14 (NCT04757337)
- Testing
- Doxorubicin, Cyclophosphamide
- Where
- France
- Volunteers
- 214 people
- Sponsor
- UNICANCER
Oropharynx Cancer
Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer
The aim of this research is to study the feasibility of neoadjuvant treatment before chemoradiation in "high risk" HPV-driven Oropharynx cancer
- Trial name
- IMMUNEBOOST (NCT03838263)
- Testing
- Nivolumab, Chemoradiation
- Where
- 11 sites in France
- Volunteers
- 62 people
- Sponsor
- UNICANCER
Squamous Cell Lung Cancer, Vulvar Cancer
Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations
Interventional study evaluating the efficacy of an immunotherapy (pembrolizumab) in combination with a targeted therapy (vorinostat) in patient with recurrent and/or metastatic squamous cell carcinoma (localisations : head and…
- Conditions
- Squamous Cell Lung Cancer, Vulvar Cancer, Penile Cancer, Cervix Cancer
- Trial name
- PEVOsq (NCT04357873)
- Testing
- pembrolizumab; vorinostat
- Where
- 14 sites in France
- Volunteers
- 112 people
- Sponsor
- UNICANCER
Extragonadal Germ Cell Tumor, Teratoma
Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extragonadal Germ Cell Tumor, Teratoma, Testicular Germ Cell Tumor
- Trial name
- NCT00104676
- Testing
- bleomycin sulfate, cisplatin, etoposide
- Where
- 24 sites in United States, France and 1 more
- Volunteers
- 263 people
- Sponsor
- UNICANCER